Table 2.

Discounted Costs, Health Outcomes, and Incremental Cost-Effectiveness Ratios by Treatment Strategy and by Patient Fibrosis Level^*

	Patient starting at F0				Patient starting at F1			Patient starting at F2
	Tx at F3	Tx at F2	Tx at F1	Tx at F0	Tx at F3	Tx at F2	Tx at F1	Tx at F3	Tx at F2
Nontreatment costs ($)	10,100	9300	8700	7900	11,200	9100	8000	12,800	8800
Treatment costs ($)	23,400	36,500	62,100	105,300	48,000	68,400	105,200	78,200	104,700
Total costs ($)	33,600	45,800	70,800	113,100	59,200	77,400	113,200	91,000	113,600
Liver disease deaths	0.01	0.00	0.00	0.00	0.01	0.00	0.00	0.03	0.01
QALYs	15.96	16.09	16.19	16.37	15.84	16.14	16.35	15.61	16.22
Treatment Policies Compared		Tx at F2 Versus Tx at F3	†	Tx at F0 Versus Tx at F2		Tx at F2 Versus Tx at F3	Tx at F1 Versus Tx at F2		Tx at F2 Versus Tx at F3
ICER ($/averted death)		2,995,000		61,326,500		1,864,700	16,957,300		1,211,300
ICER ($/QALY)		97,900		242,900		59,500	174,100		37,300

^*These results were generated using base case parameter values. All costs are presented as 2012 US dollars using a 3% annual discount rate on future costs and benefits. To simplify presentation costs and ICERs, numbers are rounded to the nearest hundred. The results focus on immediate versus delayed treatment (i.e., “treat now” versus “treat later”) for a patient starting at a given level of fibrosis. If “treat later” is not an option, the cost per QALY gained of immediate treatment (versus “never treat”) is $108,800 at F0, $47,000 at F1, and $21,400 at F2 (see Table F1 in the Supporting Information).

^†This treatment scenario was weakly dominated by the subsequent, more expansive treatment scenario (i.e., in these cases, treatment at F0 dominates treatment at F1 on a cost per QALY basis), and the ICER for treatment at F0 compares treatment at F0 to treatment at F2.

Abbreviation: Tx, treatment.